Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2016-10-28 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
关于子公司使用暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 福安药业（集团）股份有限公司 regarding the use of temporarily idle raised funds by its subsidiary for cash management. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange about the management and use of raised funds. The document details the amount of funds raised, their intended use, the approval process by the board and supervisory committee, and the independent financial advisor's opinion. It does not contain financial statements or detailed financial results but rather focuses on the company's plan and approval for managing idle raised funds. The document length is 4354 characters, which is relatively short and consistent with an announcement rather than a full report. This fits the category of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including the use of raised funds.
2016-10-28 Chinese
关于签订募集资金三方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a tripartite supervision agreement for raised funds related to a non-public issuance of shares to purchase assets and raise supporting funds. It details the amount raised, the use of funds, the opening of a special account for the funds, and the responsibilities of the parties involved in supervising the use of the funds. There are no financial statements or comprehensive financial data presented, nor is this a full report. The document is relatively short (2696 characters) and serves as a formal announcement about the agreement and fund management rather than a financial report or detailed investor presentation. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2016-10-27 Chinese
关于收到药物临床试验批件及审批意见通知件的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of drug clinical trial approval and regulatory opinions from the National Medical Products Administration (国家食品药品监督管理总局). It details specific drug approvals and rejections, and discusses the company's plans for subsequent clinical trials and R&D activities. The document is short (971 characters) and serves as a regulatory update rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed governance information. It is not an announcement of voting results, nor a capital or financing update. It is a regulatory announcement about drug approval status, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2016-10-27 Chinese
关于公司控股股东部分股份解除质押的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the release of pledged shares by a major shareholder of the company. It includes details about the shareholder, the number of shares released from pledge, and the proportion of shares involved. There is no financial report, earnings data, or management discussion. The document is an official announcement about a change in share pledge status, which relates to shareholding but not a change in major shareholding percentage crossing thresholds. It is not a full report or financial statement, nor a voting or AGM related document. This fits best under Regulatory Filings (RNS) as a general regulatory announcement about share pledge status.
2016-10-21 Chinese
关于公司控股股东部分股份质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the pledge of shares by a controlling shareholder of the company. It details the number of shares pledged, the pledgee, and the purpose of the pledge. There is no financial report, earnings data, or management discussion. The document is a specific update on capital structure related to share pledging, which falls under capital or financing activities. The document length is short and focused on a financing-related event, not a full report or announcement of a report publication. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2016-10-20 Chinese
关于收到药物临床试验批件的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of drug clinical trial approvals from the National Medical Products Administration (国家食品药品监督管理总局). It details the approval of clinical trial permits for several drugs, including their specifications and registration numbers. The document is short (986 characters) and serves as an official disclosure of regulatory approval status rather than a financial report or detailed operational update. It does not contain financial data, management changes, voting results, or other report types. It is a regulatory announcement about clinical trial approvals, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2016-10-18 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.